Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M. Kasenda B, et al. Among authors: ferlay c. Ann Oncol. 2015 Jul;26(7):1305-13. doi: 10.1093/annonc/mdv076. Epub 2015 Feb 20. Ann Oncol. 2015. PMID: 25701456 Free PMC article. Review.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY. Ghesquières H, et al. Among authors: ferlay c. Ann Oncol. 2010 Apr;21(4):842-850. doi: 10.1093/annonc/mdp529. Epub 2009 Nov 13. Ann Oncol. 2010. PMID: 19914958 Free article. Clinical Trial.
Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series.
Provencher S, Ferlay C, Alaoui-Slimani K, Devidas A, Lepretre S, de Prijck B, Sebban C, de la Fouchardiere A, Chassagne-Clement C, Ketterer N, Thyss A, Delannoy A, Tilly H, Biron P, Blay JY, Ghesquières H. Provencher S, et al. Among authors: ferlay c. Hematol Oncol. 2011 Mar;29(1):10-6. doi: 10.1002/hon.944. Hematol Oncol. 2011. PMID: 21381074
Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H. Fossard G, et al. Among authors: ferlay c. Eur J Cancer. 2017 Feb;72:12-19. doi: 10.1016/j.ejca.2016.10.036. Epub 2016 Dec 22. Eur J Cancer. 2017. PMID: 28012348
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
Ghesquières H, Stamatoullas A, Casasnovas O, Morschhauser F, Gyan E, Gabarre J, Malphettes M, Clément L, Ferlay C, Brice P. Ghesquières H, et al. Among authors: ferlay c. Leuk Lymphoma. 2013 Nov;54(11):2399-404. doi: 10.3109/10428194.2013.776165. Epub 2013 Mar 13. Leuk Lymphoma. 2013. PMID: 23410099
A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).
Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P. Sebban C, et al. Among authors: ferlay c. Eur J Cancer. 2012 Mar;48(5):713-20. doi: 10.1016/j.ejca.2011.12.016. Epub 2012 Jan 14. Eur J Cancer. 2012. PMID: 22248711 Clinical Trial.
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S. Fléchon A, et al. Among authors: ferlay c. Ann Oncol. 2011 Nov;22(11):2476-2481. doi: 10.1093/annonc/mdr004. Epub 2011 Mar 24. Ann Oncol. 2011. PMID: 21436186 Free article. Clinical Trial.
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M. Bylicki O, et al. Among authors: ferlay c. J Thorac Oncol. 2013 Jul;8(7):906-14. doi: 10.1097/JTO.0b013e31828cb505. J Thorac Oncol. 2013. PMID: 23591160 Free article. Clinical Trial.
26 results